These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Jäger U; D'Sa S; Schörgenhofer C; Bartko J; Derhaschnig U; Sillaber C; Jilma-Stohlawetz P; Fillitz M; Schenk T; Patou G; Panicker S; Parry GC; Gilbert JC; Jilma B Blood; 2019 Feb; 133(9):893-901. PubMed ID: 30559259 [TBL] [Abstract][Full Text] [Related]
4. Sutimlimab in Cold Agglutinin Disease. Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Fruebis J; Jiang X; Lin S; Reuter C; Morales-Arias J; Hobbs W; Berentsen S N Engl J Med; 2021 Apr; 384(14):1323-1334. PubMed ID: 33826820 [TBL] [Abstract][Full Text] [Related]
5. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Berentsen S; Barcellini W; D'Sa S; Jilma B Immunotherapy; 2022 Oct; 14(15):1191-1204. PubMed ID: 35946351 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Gelbenegger G; Schoergenhofer C; Derhaschnig U; Buchtele N; Sillaber C; Fillitz M; Schenk TM; D'Sa S; Cartwright R; Gilbert JC; Jilma B; Jaeger U Blood Adv; 2020 Mar; 4(6):997-1005. PubMed ID: 32176765 [TBL] [Abstract][Full Text] [Related]
7. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis. Moore DC; Arnall JR Ann Pharmacother; 2023 Aug; 57(8):970-977. PubMed ID: 36476151 [TBL] [Abstract][Full Text] [Related]
8. Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s. Simmons KT; Chan J; Hussain S; Rose EL; Markham K; Byun TS; Panicker S; Parry GC; Storek M Clin Immunol; 2023 Jun; 251():109629. PubMed ID: 37149117 [TBL] [Abstract][Full Text] [Related]
9. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Röth A; Berentsen S; Barcellini W; D'Sa S; Jilma B; Michel M; Weitz IC; Yamaguchi M; Nishimura JI; Vos JMI; Storek M; Wong N; Patel P; Jiang X; Vagge DS; Wardęcki M; Shafer F; Lee M; Broome CM Blood; 2022 Sep; 140(9):980-991. PubMed ID: 35687757 [TBL] [Abstract][Full Text] [Related]
10. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease. Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Weitz IC; Yoo R; Jayawardene D; Vagge DS; Kralova K; Shafer F; Wardȩcki M; Lee M; Berentsen S Am J Hematol; 2023 Aug; 98(8):1246-1253. PubMed ID: 37246953 [TBL] [Abstract][Full Text] [Related]
11. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Shi J; Rose EL; Singh A; Hussain S; Stagliano NE; Parry GC; Panicker S Blood; 2014 Jun; 123(26):4015-22. PubMed ID: 24695853 [TBL] [Abstract][Full Text] [Related]
12. Sutimlimab for the Treatment of Cold Agglutinin Disease. Berentsen S Hemasphere; 2023 May; 7(5):e879. PubMed ID: 37153870 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of sutimlimab in cold agglutinin disease. Ito S; Wang D; Purcell A; Chetlapalli K; Lee AI; Cuker A; Goshua G Am J Hematol; 2024 Aug; 99(8):1475-1484. PubMed ID: 38733355 [TBL] [Abstract][Full Text] [Related]
15. A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway. Bartko J; Schoergenhofer C; Schwameis M; Firbas C; Beliveau M; Chang C; Marier JF; Nix D; Gilbert JC; Panicker S; Jilma B Clin Pharmacol Ther; 2018 Oct; 104(4):655-663. PubMed ID: 29737533 [TBL] [Abstract][Full Text] [Related]
16. Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease. Frank T; Kovar A; Strougo A; Vage C; Teuscher N; Wong N J Pharmacol Exp Ther; 2023 Aug; 386(2):143-155. PubMed ID: 37164370 [TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B. Röth A; Berentsen S; Barcellini W; D'Sa S; Jilma B; Michel M; Weitz IC; Yamaguchi M; Nishimura JI; Vos JMI; Cid J; Storek M; Wong N; Yoo R; Jayawardene D; Srivastava S; Wardęcki M; Shafer F; Lee M; Broome CM EClinicalMedicine; 2024 Aug; 74():102733. PubMed ID: 39091672 [TBL] [Abstract][Full Text] [Related]
18. Novel Monoclonal Antibody Therapy in a Patient With Treatment-Refractory Warm Autoimmune Hemolytic Anemia. Tahhan F; Huynh B; Xu P Cureus; 2022 Jun; 14(6):e26051. PubMed ID: 35747120 [TBL] [Abstract][Full Text] [Related]
19. Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. Roth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Weitz IC; Patel P; Jiang X; Reuter C; Su J; Shafer F; Lee M; Berentsen S Haematologica; 2022 Jul; 107(7):1698-1702. PubMed ID: 35172561 [No Abstract] [Full Text] [Related]
20. The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease. Barcellini W; Fattizzo B Expert Rev Hematol; 2024 Jul; 17(7):287-294. PubMed ID: 38872338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]